explore -WSS

explore

author：comprehensive 2025-10-02 19:39:49 - browse：214

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Liver decline slowed by off

leisure time

WSS

A public health expert passes on football's full body collisions for youths

FDA approves first new drug developed for postpartum depression

At flashy new research hub, AstraZeneca lays out ambitious growth goals

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Bispecific antibodies are next new thing in cancer immunotherapy

hotspot

explore

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

The cancer drug shortage isn’t new — and neither are the solutions

Eyeing GLP

Novavax promises a turnaround & Lilly roils the obesity market

Biogen joins immunology wave with $1.15 billion acquisition of HI

Psychedelics group wrestles with new pharma identity

As a primary care physician, here's how I hope to partner with AI

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Timeline: Key moments in fight for gay rights

Wikipedia

Can medical device makers keep up in the race to treat obesity?

Novo pauses ads for weight loss drug Wegovy amid demand

Reports of telehealth's death have been greatly exaggerated

FDA poised to publish guidelines for clinical trial diversity

Altering the blood type of lungs raises potential for universal organs for transplants

Biogen joins immunology wave with $1.15 billion acquisition of HI

hotspot

knowledge

leisure time

hotspot